{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:49:44Z","timestamp":1794692984881,"version":"4.9.1"},"reference-count":353,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.metabol.2024.156064","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:19:14Z","timestamp":1731572354000},"page":"156064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["PCSK9 in metabolism and diseases"],"prefix":"10.1016","volume":"163","author":[{"given":"Amir","family":"Ajoolabady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pratico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Mazidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian G.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Seidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156064_bb0005","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2024.156064_bb0015","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOL.0000000000000180","article-title":"Role of PCSK9 beyond liver involvement","volume":"26","author":"Cariou","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-017-0619-0","article-title":"Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease","volume":"112","author":"Glerup","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/cancers15051397","article-title":"PCSK9 inhibitors in cancer patients treated with immune-checkpoint inhibitors to reduce cardiovascular events: new frontiers in cardioncology","volume":"15","author":"Quagliariello","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.metabol.2024.156064_bb0040","doi-asserted-by":"crossref","first-page":"502","DOI":"10.34172\/apb.2020.062","article-title":"PCSK9: a key target for the treatment of cardiovascular disease (CVD)","volume":"10","author":"Sobati","year":"2020","journal-title":"Advanced Pharmaceutical Bulletin"},{"key":"10.1016\/j.metabol.2024.156064_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.metabol.2024.156064_bb0050","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/jcm10081758","article-title":"PCSK9 and the gut-liver-brain axis: a novel therapeutic target for immune regulation in alcohol use disorder","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC\u20101\/PCSK9 in the development of the nervous system","volume":"98","author":"Poirier","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.metabol.2024.156064_bb0060","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","article-title":"The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis","volume":"70","author":"Bayes-Genis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/pr.116.012989","article-title":"The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9","volume":"69","author":"Seidah","year":"2017","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2024.156064_bb0070","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0080","first-page":"1135","article-title":"The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol","volume":"7","author":"Poirier","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.metabol.2024.156064_bb0085","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pro.3019","article-title":"Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor","volume":"25","author":"Garvie","year":"2016","journal-title":"Protein Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2014.08.038","article-title":"Sorting an LDL receptor with bound PCSK9 to intracellular degradation","volume":"237","author":"Leren","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0095","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.metabol.2024.156064_bb0100","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0105","first-page":"184","article-title":"PCSK9: an enigmatic protease. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of","volume":"1781","author":"Lopez","year":"2008","journal-title":"Lipids"},{"key":"10.1016\/j.metabol.2024.156064_bb0110","doi-asserted-by":"crossref","first-page":"40965","DOI":"10.1074\/jbc.M110.154815","article-title":"Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events","volume":"285","author":"Benjannet","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0115","doi-asserted-by":"crossref","first-page":"31791","DOI":"10.1074\/jbc.M805971200","article-title":"Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels","volume":"283","author":"Mayer","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041865","article-title":"Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation","volume":"7","author":"Seidah","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","article-title":"PCSK9 and diabetes: is there a link?","volume":"22","author":"Momtazi","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.metabol.2024.156064_bb0130","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgmr.2016.11.003","article-title":"Studies of the autoinhibitory segment comprising residues 31\u201360 of the prodomain of PCSK9: possible implications for the mechanism underlying gain-of-function mutations","volume":"9","author":"Wier\u00f8d","year":"2016","journal-title":"Molecular Genetics and Metabolism Reports"},{"key":"10.1016\/j.metabol.2024.156064_bb0135","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1074\/jbc.RA119.010221","article-title":"A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles","volume":"295","author":"Sarkar","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.960272","article-title":"Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding","volume":"13","author":"Sarkar","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0145","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2024.156064_bb0150","doi-asserted-by":"crossref","unstructured":"Gaillard CF, Ouadda ABD, Ciccone L, Girard E, Mikaeeli S, Evagelidis A, et al. Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels. bioRxiv. 2022.","DOI":"10.1101\/2022.10.20.513093"},{"key":"10.1016\/j.metabol.2024.156064_bb0155","doi-asserted-by":"crossref","first-page":"10805","DOI":"10.1074\/jbc.M113.453373","article-title":"Characterization of proprotein convertase subtilisin\/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2)","volume":"288","author":"DeVay","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0160","doi-asserted-by":"crossref","first-page":"18609","DOI":"10.1074\/jbc.M115.647180","article-title":"Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertase-mediated low density lipoprotein receptor degradation but interact with each other","volume":"290","author":"Butkinaree","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2121-8-9","article-title":"Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly","volume":"8","author":"Holla","year":"2007","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0170","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0175","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2008.10.027","article-title":"Degradation of LDLR protein mediated by \u2018gain of function\u2019 PCSK9 mutants in normal and ARH cells","volume":"203","author":"Fasano","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0180","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2024.156064_bb0185","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1073\/pnas.1114128109","article-title":"Atomic structure of the autosomal recessive hypercholesterolemia phosphotyrosine-binding domain in complex with the LDL-receptor tail","volume":"109","author":"Dvir","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0190","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0195","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0200","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacl.2016.07.004","article-title":"A review of PCSK9 inhibition and its effects beyond LDL receptors","volume":"10","author":"Dixon","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb0205","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb0215","series-title":"New insights into LDLR regulation and trafficking: the interplay of non-lipid-related molecules with PCSK9","author":"Mikaeeli","year":"2023"},{"key":"10.1016\/j.metabol.2024.156064_bb0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1194\/jlr.M078360","article-title":"PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction","volume":"59","author":"Sun","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0225","doi-asserted-by":"crossref","first-page":"34114","DOI":"10.1074\/jbc.M305417200","article-title":"Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2)","volume":"278","author":"Shin","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110802","article-title":"Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK\/SREBP-2\/PCSK9\/LDLR signalling pathway","volume":"133","author":"Li","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2024.156064_bb0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2s","volume":"49","author":"Jeong","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0240","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1194\/jlr.M052969","article-title":"Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1\u03b1 in normolipidemic mice [S]","volume":"56","author":"Shende","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0245","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1\u03b1 plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0250","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1042\/BJ20111645","article-title":"The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells","volume":"443","author":"Li","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.metabol.2024.156064_bb0255","doi-asserted-by":"crossref","first-page":"29252","DOI":"10.1074\/jbc.M113.481473","article-title":"FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin\/kexin type 9 (Pcsk9) gene expression","volume":"288","author":"Tao","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0260","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.M028969","article-title":"Differential effects of estrogen\/androgen on the prevention of nonalcoholic fatty liver disease in the male rat [S]","volume":"54","author":"Zhang","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0265","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/cvr\/cvq349","article-title":"Insulin says NO to cardiovascular disease","volume":"89","author":"Yu","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0270","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0275","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/ATVBAHA.115.305688","article-title":"Role of insulin in the regulation of proprotein convertase subtilisin\/kexin type 9","volume":"35","author":"Miao","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0280","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic \u03b4-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2024.156064_bb0285","article-title":"Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice","volume":"1866","author":"Peyot","year":"2021","journal-title":"Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids"},{"key":"10.1016\/j.metabol.2024.156064_bb0290","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.metabol.2024.156064_bb0295","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor","volume":"40","author":"Da Dalt","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155291","article-title":"Pancreatic PCSK9 controls the organization of the \u03b2-cell secretory pathway via LDLR-cholesterol axis","volume":"136","author":"Marku","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156064_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102096","article-title":"Proprotein convertase PCSK9 affects expression of key surface proteins in human pancreatic beta cells via intracellular and extracellular regulatory circuits","volume":"298","author":"Saitoski","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2021.03.044","article-title":"Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function","volume":"326","author":"Ramin-Mangata","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon receptor signaling and lipid metabolism","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0320","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCRESAHA.118.313648","article-title":"Hepatic glucagon signaling regulates PCSK9 and low-density lipoprotein cholesterol","volume":"124","author":"Spolitu","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MAJ.0000000000000512","article-title":"Estrogen and cardiovascular disease: is timing everything?","volume":"350","author":"Giordano","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0330","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1194\/jlr.M055780","article-title":"Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol","volume":"56","author":"Ghosh","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0335","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156064_bb0340","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejphar.2019.05.019","article-title":"Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor \u03b1-mediated pathway in L02 cells","volume":"855","author":"Jing","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb0345","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cca.2015.03.036","article-title":"Relationship between testosterone, estradiol and circulating PCSK9: cross-sectional and interventional studies in humans","volume":"446","author":"Ooi","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2024.156064_bb0350","article-title":"17\u03b2-Estradiol inhibits PCSK9-mediated LDLR degradation through GPER\/PLC activation in HepG2 cells","volume":"930","author":"Fu","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2024.156064_bb0355","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.metabol.2015.01.009","article-title":"The effects of estrogen on serum level and hepatocyte expression of PCSK9","volume":"64","author":"Guo","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156064_bb0360","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.111.242461","article-title":"Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women","volume":"32","author":"Persson","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0365","article-title":"PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: role of hepatic cholesterol","volume":"1867","author":"Roubtsova","year":"2022","journal-title":"Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids"},{"issue":"42\u201351","key":"10.1016\/j.metabol.2024.156064_bb0370","first-page":"4","article-title":"Atherogenesis: why women live longer than men","volume":"40","author":"Hazzard","year":"1985","journal-title":"Geriatrics (Basel, Switzerland)"},{"key":"10.1016\/j.metabol.2024.156064_bb0375","first-page":"161","article-title":"Adipokines and cardiovascular disease: a comprehensive review","author":"Smekal","year":"2017","journal-title":"Biomedical Papers of the Medical Faculty of Palacky University in Olomouc"},{"key":"10.1016\/j.metabol.2024.156064_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1032-4","article-title":"Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity","volume":"14","author":"Du","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113216","article-title":"Current status and future prospects of p38\u03b1\/MAPK14 kinase and its inhibitors","volume":"213","author":"Madkour","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2011.11.019","article-title":"Structure-based design, synthesis and biological evaluation of N-pyrazole, N\u2032-thiazole urea inhibitors of MAP kinase p38\u03b1","volume":"48","author":"Getlik","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0395","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.bmcl.2014.05.080","article-title":"Synthesis and structure\u2013activity relationships of 4-fluorophenyl-imidazole p38\u03b1 MAPK, CK1\u03b4 and JAK2 kinase inhibitors","volume":"24","author":"Seerden","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.metabol.2024.156064_bb0400","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1016\/j.bmcl.2011.04.121","article-title":"Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase","volume":"21","author":"Selness","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.metabol.2024.156064_bb0405","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.ajpath.2020.07.016","article-title":"Leptin, resistin, and proprotein convertase subtilisin\/kexin type 9: the role of STAT3","volume":"190","author":"Macchi","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.metabol.2024.156064_bb0410","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/en.2015-1624","article-title":"Effect of leptin replacement on PCSK9 in ob\/ob mice and female lipodystrophic patients","volume":"157","author":"Levenson","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2024.156064_bb0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabet.2016.08.004","article-title":"One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes","volume":"43","author":"Vatier","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2024.156064_bb0420","first-page":"10","article-title":"Natriuretic peptide system and cardiovascular disease","volume":"11","author":"Federico","year":"2010","journal-title":"Heart Views: the Official Journal of the Gulf Heart Association"},{"key":"10.1016\/j.metabol.2024.156064_bb0425","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/ijms20020245","article-title":"PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides","volume":"20","author":"Bordicchia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0430","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.atherosclerosis.2013.01.023","article-title":"PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells","volume":"227","author":"Levy","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0435","first-page":"257","article-title":"Acidity and lipolysis by group V secreted phospholipase A2 strongly increase the binding of apoB-100-containing lipoproteins to human aortic proteoglycans. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of","volume":"1821","author":"L\u00e4hdesm\u00e4ki","year":"2012","journal-title":"Lipids"},{"key":"10.1016\/j.metabol.2024.156064_bb0440","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0445","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tibs.2007.02.001","article-title":"ABCA1: at the nexus of cholesterol, HDL and atherosclerosis","volume":"32","author":"Attie","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113789","article-title":"Akt inhibition promotes ABCA1-mediated cholesterol efflux to ApoA-I through suppressing mTORC1","volume":"9","author":"Dong","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","article-title":"Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages","volume":"256","author":"Adorni","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0460","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tox.2019.02.015","article-title":"Caffeine programs hepatic SIRT1-related cholesterol synthesis and hypercholesterolemia via A2AR\/cAMP\/PKA pathway in adult male offspring rats","volume":"418","author":"Hu","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/j.metabol.2024.156064_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-28240-9","article-title":"Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance","volume":"13","author":"Lebeau","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156064_bb0470","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.celrep.2015.11.006","article-title":"GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation","volume":"13","author":"Poirier","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb0475","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1161\/ATVBAHA.120.315708","article-title":"New insight into metformin-induced cholesterol-lowering effect crosstalk between glucose and cholesterol homeostasis via ChREBP (carbohydrate-responsive element-binding protein)-mediated PCSK9 (proprotein convertase subtilisin\/kexin type 9) regulation","volume":"41","author":"Hu","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0480","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijgo.2004.08.015","article-title":"Metformin therapy in women with polycystic ovary syndrome","volume":"87","author":"Aruna","year":"2004","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.metabol.2024.156064_bb0485","first-page":"2","article-title":"E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver","author":"Lai","year":"2017","journal-title":"JCI insight"},{"key":"10.1016\/j.metabol.2024.156064_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106072","article-title":"Melatonin-based therapeutics for atherosclerotic lesions and beyond: focusing on macrophage mitophagy","volume":"176","author":"Ajoolabady","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0495","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0500","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/cvr\/cvaa254","article-title":"PCSK9 and LRP5 in macrophage lipid internalization and inflammation","volume":"117","author":"Badimon","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0505","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0510","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrrheum.2015.158","article-title":"Does lipopolysaccharide-mediated inflammation have a role in OA?","volume":"12","author":"Huang","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.metabol.2024.156064_bb0515","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2024.156064_bb0520","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1002\/ptr.8260","article-title":"The role of natural products as PCSK9 modulators: a review","volume":"38","author":"Khayatan","year":"2024","journal-title":"Phytother Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0525","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107058","article-title":"Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?","volume":"200","author":"Domingo","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0535","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12931-024-02842-x","article-title":"Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice","volume":"25","author":"Liang","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0540","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/med-2021-0400","article-title":"Leptin and PCSK9 concentrations are associated with vascular endothelial cytokines in patients with stable coronary heart disease","volume":"17","author":"Wang","year":"2022","journal-title":"Open Medicine"},{"key":"10.1016\/j.metabol.2024.156064_bb0545","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","article-title":"Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease","volume":"234","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0550","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","article-title":"Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease","volume":"8","author":"Zhang","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb0555","article-title":"The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease","volume":"22","author":"Li","year":"2014","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.metabol.2024.156064_bb0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4093\/dmj.2017.0081","article-title":"Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome","volume":"42","author":"Bae","year":"2018","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2024.156064_bb0565","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211051292","article-title":"Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines","volume":"11","author":"Zhong","year":"2021","journal-title":"Pulmonary Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb0570","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.016482","article-title":"Association of circulating PCSK9 with ischemia-reperfusion injury in acute ST-elevation myocardial infarction. Circulation","volume":"17","author":"Tiller","year":"2024","journal-title":"Cardiovascular Imaging"},{"key":"10.1016\/j.metabol.2024.156064_bb0575","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s13273-023-00352-3","article-title":"PCSK9 regulates myocardial ischemia\u2013reperfusion injury through parkin\/pink1-mediated autophagy pathway","volume":"20","author":"Huang","year":"2024","journal-title":"Molecular & Cellular Toxicology"},{"key":"10.1016\/j.metabol.2024.156064_bb0580","doi-asserted-by":"crossref","unstructured":"Benedetti A, Del Monte A. Is PCSK9 the Key Player in the Ischemia-Reperfusion Match? : Lippincott Williams & Wilkins Hagerstown, MD; 2024. p. e017210.","DOI":"10.1161\/CIRCIMAGING.124.017210"},{"issue":"ehy566","key":"10.1016\/j.metabol.2024.156064_bb0585","first-page":"5003","article-title":"5003 inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia\/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation","volume":"39","author":"Palee","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb0590","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJMe1509718","article-title":"Targeting myocardial reperfusion injury\u2014the search continues","volume":"373","author":"Hausenloy","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0595","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40200-020-00557-6","article-title":"Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials","volume":"19","author":"Cordero","year":"2020","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.metabol.2024.156064_bb0600","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(08)61237-4","article-title":"Acute myocardial infarction","volume":"372","author":"White","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.metabol.2024.156064_bb0605","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ahj.2024.06.004","article-title":"PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double-blind, placebo-controlled, multicenter SHAWN study","volume":"277","author":"Wu","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1339487","article-title":"PCSK9 inhibition: from effectiveness to cost-effectiveness","volume":"11","author":"Mercep","year":"2024","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10.1016\/j.metabol.2024.156064_bb0615","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"issue":"ehy564","key":"10.1016\/j.metabol.2024.156064_bb0620","first-page":"P945","article-title":"P945 PCSK9 deficiency is not associated with impaired cardiac repair capacity early after myocardial infarction","volume":"39","author":"Winter","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb0625","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0630","first-page":"1","article-title":"Sex differences associated with circulating PCSK9 in patients presenting with acute myocardial infarction","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb0635","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ehf2.12533","article-title":"Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study","volume":"7","author":"Mi\u00f1ana","year":"2020","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.metabol.2024.156064_bb0640","first-page":"568","article-title":"Circulating PCSK9 and risk of myocardial infarction: the HUNT study in Norway","volume":"1","author":"Laugsand","year":"2016","journal-title":"JACC: Basic To Translational Science"},{"key":"10.1016\/j.metabol.2024.156064_bb0645","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.numecd.2020.11.010","article-title":"PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction","volume":"31","author":"Zeller","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2024.156064_bb0650","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000493785","article-title":"Acute-phase plasma PCSK9 levels and recurrent cardiovascular events in a Chinese acute myocardial infarction cohort","volume":"141","author":"Gao","year":"2018","journal-title":"Cardiology"},{"key":"10.1016\/j.metabol.2024.156064_bb0655","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun"},{"key":"10.1016\/j.metabol.2024.156064_bb0660","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb0665","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0670","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7754\/Clin.Lab.2012.121104","article-title":"Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs","volume":"59","author":"Wu","year":"2013","journal-title":"Clin Lab"},{"key":"10.1016\/j.metabol.2024.156064_bb0675","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cca.2014.01.043","article-title":"PCSK9 gene mutations and low-density lipoprotein cholesterol","volume":"431","author":"Wu","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2024.156064_bb0680","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb0685","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2024.156064_bb0690","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.2174\/0109298673262124231102042914","article-title":"The link between miRNAs and PCKS9 in atherosclerosis","volume":"31","author":"Macvanin","year":"2024","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0695","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.13794","article-title":"Platelets as an inter-player between hyperlipidaemia and atherosclerosis","volume":"296","author":"Li","year":"2024","journal-title":"J Intern Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0700","doi-asserted-by":"crossref","DOI":"10.1097\/01.hjh.0000548741.50483.d3","article-title":"A6967 correlation between PCSK9 and level of inflammation in atherosclerotic plaques in patients with coronary heart disease","volume":"36","author":"Mohammed","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2024.156064_bb0705","first-page":"2789","article-title":"PCSK9 stimulates Syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor. Nature","volume":"15","author":"Shin","year":"2024","journal-title":"Communications"},{"key":"10.1016\/j.metabol.2024.156064_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116314","article-title":"PCSK9 aggravated carotid artery stenosis in ApoE\u2212\/\u2212mice by promoting the expression of tissue factors in endothelial cells via the TLR4\/NF-\u03baB pathway","volume":"225","author":"Peng","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb0715","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2016.04.103","article-title":"Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: a cohort study","volume":"215","author":"Xie","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0720","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/biomedicines9070841","article-title":"Relationship between circulating PCSK9 and markers of subclinical atherosclerosis\u2014the IMPROVE Study","volume":"9","author":"Coggi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.metabol.2024.156064_bb0725","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCRESAHA.120.316242","article-title":"Gut microbiota and cardiovascular disease","volume":"127","author":"Witkowski","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0730","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13377","article-title":"Gut microbiota and vitamin status in persons with obesity: a key interplay","volume":"23","author":"Voland","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2024.156064_bb0735","doi-asserted-by":"crossref","unstructured":"KV CR. Heart-gut axis: targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9) to prevent cardiovascular disease through gut microbiota. Medicine in Microecology 2021;7:100033.","DOI":"10.1016\/j.medmic.2021.100033"},{"key":"10.1016\/j.metabol.2024.156064_bb0740","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.cell.2021.06.019","article-title":"Gut-microbiota-targeted diets modulate human immune status","volume":"184","author":"Wastyk","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2024.156064_bb0745","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jare.2023.09.007","article-title":"Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling","volume":"61","author":"Han","year":"2024","journal-title":"Journal of Advanced Research"},{"issue":"5","key":"10.1016\/j.metabol.2024.156064_bb0750","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000538551","article-title":"Drug target Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and atrial fibrillation","volume":"149","author":"Li","year":"2024","journal-title":"Cardiology"},{"key":"10.1016\/j.metabol.2024.156064_bb0755","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0760","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 biology and its role in atherothrombosis","volume":"22","author":"Barale","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0765","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ejcts.2008.12.042","article-title":"Mitral valve surgery plus concomitant atrial fibrillation ablation is superior to mitral valve surgery alone with an intensive rhythm control strategy","volume":"35","author":"von Oppell","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.metabol.2024.156064_bb0770","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/antiox9040296","article-title":"PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation","volume":"9","author":"Cammisotto","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.metabol.2024.156064_bb0775","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2019.07.002","article-title":"Interaction between serum endotoxemia and proprotein convertase subtilisin\/kexin 9 (PCSK9) in patients with atrial fibrillation: a post-hoc analysis from the ATHERO-AF cohort","volume":"289","author":"Pastori","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb0780","first-page":"1","article-title":"The role of PCSK9 in heart failure and other cardiovascular diseases\u2014mechanisms of action beyond its effect on LDL cholesterol","author":"Dutka","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.metabol.2024.156064_bb0785","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12920-024-01826-6","article-title":"Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9","volume":"17","author":"Lin","year":"2024","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.metabol.2024.156064_bb0790","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","article-title":"PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction","volume":"42","author":"Da Dalt","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcp.2014.09.001","article-title":"PCSK9 polymorphism in a Tunisian cohort: identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk","volume":"29","author":"Slimani","year":"2015","journal-title":"Mol Cell Probes"},{"key":"10.1016\/j.metabol.2024.156064_bb0800","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12031-014-0238-2","article-title":"Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a Tunisian cohort","volume":"53","author":"Slimani","year":"2014","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.metabol.2024.156064_bb0805","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/ATVBAHA.119.313247","article-title":"Ser-phosphorylation of PCSK9 (proprotein convertase subtilisin-kexin 9) by Fam20C (family with sequence similarity 20, member C) kinase enhances its ability to degrade the LDLR (low-density lipoprotein receptor)","volume":"39","author":"Ben Djoudi Ouadda","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb0810","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2024.156064_bb0815","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2350-7-66","article-title":"The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women","volume":"7","author":"Evans","year":"2006","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.metabol.2024.156064_bb0820","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.apjtm.2016.01.008","article-title":"E670G polymorphism of PCSK9 gene of patients with coronary heart disease among Han population in Hainan and three provinces in the northeast of China","volume":"9","author":"He","year":"2016","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0825","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/CS20070150","article-title":"The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men","volume":"113","author":"Scartezini","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.metabol.2024.156064_bb0830","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1515\/CCLM.2009.032","article-title":"The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan","volume":"47","author":"Hsu","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0835","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.clinbiochem.2013.01.013","article-title":"Association between PCSK9 and LDLR gene polymorphisms with coronary heart disease: case-control study and meta-analysis","volume":"46","author":"Zhang","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.metabol.2024.156064_bb0840","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2007.02.057","article-title":"Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study)","volume":"100","author":"Hallman","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0845","article-title":"PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites. Circulation: Cardiovascular","volume":"10","author":"Kent","year":"2017","journal-title":"Genetics"},{"key":"10.1016\/j.metabol.2024.156064_bb0850","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0855","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb0860","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.metabol.2024.156064_bb0865","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-024-02435-0","article-title":"The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy","volume":"41","author":"Hsu","year":"2024","journal-title":"Med Oncol"},{"key":"10.1016\/j.metabol.2024.156064_bb0870","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12885-024-12148-2","article-title":"Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.metabol.2024.156064_bb0875","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-018-06467-9","article-title":"A Mendelian randomization study of the effects of blood lipids on breast cancer risk","volume":"9","author":"Nowak","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156064_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188581","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): a potential multifaceted player in cancer","volume":"1876","author":"Bhattacharya","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.metabol.2024.156064_bb0885","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-022-10120-6","article-title":"Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers","volume":"22","author":"Wong Chong","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.metabol.2024.156064_bb0890","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.3390\/ijms21207802","article-title":"NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells","volume":"21","author":"Quagliariello","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb0895","article-title":"Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2024.156064_bb0900","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.598649","article-title":"Coming back to physiology: extra hepatic functions of proprotein convertase subtilisin\/kexin type 9","volume":"11","author":"Schl\u00fcter","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2024.156064_bb0905","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.metabol.2024.156064_bb0910","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cvr\/cvz003","article-title":"Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies","volume":"115","author":"Seidah","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0915","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.21873\/anticanres.11145","article-title":"Immune blockade inhibition in breast cancer","volume":"36","author":"Voutsadakis","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0920","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s12272-016-0850-5","article-title":"Immune checkpoint inhibitors for cancer treatment","volume":"39","author":"Park","year":"2016","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0925","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156064_bb0930","doi-asserted-by":"crossref","unstructured":"Gaillard CF, Djoudi Ouadda AB, Ciccone L, Girard E, Mikaeeli S, Evagelidis A, et al. Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels. bioRxiv. 2022:2022.10.20.513093.","DOI":"10.1101\/2022.10.20.513093"},{"key":"10.1016\/j.metabol.2024.156064_bb0935","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0940","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb0945","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb0950","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156064_bb0955","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jacl.2017.04.001","article-title":"Can iPCSK9-induced hypocholesterolemia starve cancer cells?","volume":"11","author":"Gangloff","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb0960","first-page":"2395","volume":"379","author":"Conroy","year":"2018","journal-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer"},{"key":"10.1016\/j.metabol.2024.156064_bb0965","first-page":"14","article-title":"Cancer cells promote phenotypic alterations in hepatocytes at the edge of cancer cell nests to facilitate vessel co-option establishment in colorectal cancer liver metastases","author":"Rada","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.metabol.2024.156064_bb0970","article-title":"High levels of serum cholesterol positively correlate with the risk of the development of vessel co-opting tumours in colorectal cancer liver metastases","author":"Rada","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.metabol.2024.156064_bb0975","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/v13071229","article-title":"How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread?","volume":"13","author":"Seidah","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.metabol.2024.156064_bb0980","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156064_bb0985","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12934-024-02355-8","article-title":"Potential use of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition and prevention method in viral infection","volume":"23","author":"Muzammil","year":"2024","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.metabol.2024.156064_bb0990","doi-asserted-by":"crossref","unstructured":"Arsh H, Kumar FM, Simran F, Tamang S, ur Rehman M, Ahmed G, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Annals of Medicine and Surgery 2024;86:899\u2013908.","DOI":"10.1097\/MS9.0000000000001601"},{"key":"10.1016\/j.metabol.2024.156064_bb0995","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1172\/JCI137536","article-title":"Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes","volume":"130","author":"Gan","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2024.156064_bb1000","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2024.156064_bb1005","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bcp.2014.11.013","article-title":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications","volume":"93","author":"Tikoo","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb1010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00380-016-0936-5","article-title":"The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts","volume":"32","author":"Shin","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.metabol.2024.156064_bb1015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","article-title":"In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19","volume":"32","author":"Zhang","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.156064_bb1020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74492-0","article-title":"Statin use is associated with lower disease severity in COVID-19 infection","volume":"10","author":"Tan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb1025","doi-asserted-by":"crossref","unstructured":"Memel ZN, Lee JJ, Foulkes AS, Chung RT, Thaweethai T, Bloom PP. Statins are associated with improved 28-day mortality in patients hospitalized with SARS-CoV-2 infection. medRxiv. 2021.","DOI":"10.1101\/2021.03.27.21254373"},{"key":"10.1016\/j.metabol.2024.156064_bb1030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2020.06.006","article-title":"Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia","volume":"14","author":"Vuorio","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.10.001","article-title":"Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: results from the CORONADO study","volume":"47","author":"Cariou","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2024.156064_bb1040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/joim.13210","article-title":"PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia","volume":"289","author":"Vuorio","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1045","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020"},{"key":"10.1016\/j.metabol.2024.156064_bb1050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2012.05.012","article-title":"Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity","volume":"12","author":"Gudleski-O\u2019Regan","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.metabol.2024.156064_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119310","article-title":"HMGB1\/RAGE\/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis","volume":"273","author":"Abuelezz","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb1060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2017.08.020","article-title":"Treatment-induced viral cure of hepatitis C virus-infected patients involves a dynamic interplay among three important molecular players in lipid homeostasis: circulating microRNA (miR)-24, miR-223, and proprotein convertase subtilisin\/kexin type 9","volume":"23","author":"Hyrina","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.metabol.2024.156064_bb1065","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.amjmed.2007.01.035","article-title":"Sepsis","volume":"120","author":"O\u2019Brien","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1070","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S2352-4642(24)00140-8","article-title":"The burden and contemporary epidemiology of sepsis in children","volume":"8","author":"Watson","year":"2024","journal-title":"The Lancet Child & Adolescent Health"},{"key":"10.1016\/j.metabol.2024.156064_bb1075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2589-7500(24)00141-9","article-title":"Digital solutions in paediatric sepsis: current state, challenges, and opportunities to improve care around the world","volume":"6","author":"Sanchez-Pinto","year":"2024","journal-title":"The Lancet Digital Health"},{"key":"10.1016\/j.metabol.2024.156064_bb1080","doi-asserted-by":"crossref","unstructured":"Yuan Y, Wu W, Sun S, Zhang Y, Chen Z. PCSK9: a potential therapeutic target for sepsis. J Immunol Res 2020;2020.","DOI":"10.1155\/2020\/2687692"},{"key":"10.1016\/j.metabol.2024.156064_bb1085","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1194\/jlr.M076844","article-title":"Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice","volume":"58","author":"Berger","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.35772\/ghm.2020.01078","article-title":"Secondary dyslipidemia: its treatments and association with atherosclerosis","volume":"3","author":"Yanai","year":"2021","journal-title":"Global Health & Medicine"},{"key":"10.1016\/j.metabol.2024.156064_bb1095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0889-8529(18)30324-4","article-title":"Acquired hyperlipidemia (secondary dyslipoproteinemias)","volume":"19","author":"Chait","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.metabol.2024.156064_bb1100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-022-01542-4","article-title":"PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2024.156064_bb1105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","article-title":"Role of PCSK9 in lipid metabolism and atherosclerosis","volume":"104","author":"Lin","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2024.156064_bb1110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MOL.0000000000000601","article-title":"Proprotein convertase subtilisin\/kexin type 9 and lipid metabolism","volume":"30","author":"Spolitu","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb1115","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3389\/fgene.2020.01020","article-title":"PCSK9 variants in familial hypercholesterolemia: a comprehensive synopsis","volume":"11","author":"Guo","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.metabol.2024.156064_bb1120","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1210\/clinem\/dgab876","article-title":"New therapies for primary hyperlipidemia","volume":"107","author":"Aguilar-Salinas","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.metabol.2024.156064_bb1125","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1130","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156064_bb1135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2019.07.023","article-title":"Functional role of gut microbiota and PCSK9 in the pathogenesis of diabetes mellitus and cardiovascular disease","volume":"289","author":"Morelli","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb1140","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2024.156064_bb1145","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jid.2020.05.115","article-title":"Characterization of PCSK9 in the blood and skin of psoriasis","volume":"141","author":"Garshick","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1016\/j.metabol.2024.156064_bb1150","series-title":"Clinical management of dyslipidemia in youth with chronic kidney disease","author":"De La Torre","year":"2021"},{"key":"10.1016\/j.metabol.2024.156064_bb1155","doi-asserted-by":"crossref","DOI":"10.3390\/nu13093138","article-title":"Dietary lipids and dyslipidemia in chronic kidney disease","volume":"13","author":"Kochan","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2024.156064_bb1160","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5527\/wjn.v1.i6.184","article-title":"Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins","volume":"1","author":"Scarpioni","year":"2012","journal-title":"World Journal of Nephrology"},{"key":"10.1016\/j.metabol.2024.156064_bb1165","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"56","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2024.156064_bb1170","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.metabol.2024.156064_bb1175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nefroe.2024.01.015","article-title":"Treatment with PCSK9 inhibitors in patients with chronic kidney disease at very high cardiovascular risk","volume":"43","author":"Amaro","year":"2023","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"10.1016\/j.metabol.2024.156064_bb1180","first-page":"1","volume":"3","author":"Defesche","year":"2017","journal-title":"Familial hypercholesterolaemia Nature Reviews Disease Primers"},{"key":"10.1016\/j.metabol.2024.156064_bb1185","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.cjca.2022.05.002","article-title":"The detection, evaluation, and management of dyslipidemia in children and adolescents: a Canadian Cardiovascular Society\/Canadian Pediatric Cardiology Association clinical practice update","volume":"38","author":"Khoury","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb1190","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association","volume":"139","author":"De Ferranti","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb1195","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb1200","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1205","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/jamacardio.2016.5395","article-title":"Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb1215","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.2016.3670","article-title":"PCSK9 inhibitors for statin intolerance?","volume":"315","author":"Waters","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2024.156064_bb1220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101444","article-title":"Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): a retrospective analysis from a single center in China","volume":"71","author":"Liu","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.metabol.2024.156064_bb1230","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials","volume":"39","author":"Koskinas","year":"2018","journal-title":"Eur Heart J"},{"issue":"ehab724","key":"10.1016\/j.metabol.2024.156064_bb1235","first-page":"2583","article-title":"LDLc reduction with fixed-dose combination rosuvastatin-ezetimibe in patients with coronary heart disease that are not candidates for PCSK9 inhibitors treatment","volume":"42","author":"Cordero","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb1240","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.metabol.2024.156064_bb1245","doi-asserted-by":"crossref","unstructured":"Pandey A, Bajaj H, Garg V, Pandey A, Verma S. PCSK9 inhibition: real world application and challenges to achieve unmet cholesterol targets in Canadian atherosclerotic heart disease, the practical study. Journal of the American College of Cardiology. 2018;71:A1755-A.","DOI":"10.1016\/S0735-1097(18)32296-4"},{"key":"10.1016\/j.metabol.2024.156064_bb1250","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cardfail.2021.02.018","article-title":"PCSK9 inhibitors in heart transplant patients: safety, efficacy, and angiographic correlates","volume":"27","author":"Sammour","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.metabol.2024.156064_bb1255","doi-asserted-by":"crossref","first-page":"16659","DOI":"10.1074\/jbc.M116.717736","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation","volume":"291","author":"Weider","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11095-016-2054-6","article-title":"Population pharmacokinetics (PK) and pharmacodynamics (PD) analysis of LY3015014, a monoclonal antibody to protein convertase subtilisin\/kexin type 9 (PCSK9) in healthy subjects and hypercholesterolemia patients","volume":"34","author":"Shen","year":"2017","journal-title":"Pharm Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/protein\/gzq097","article-title":"Adnectins: engineered target-binding protein therapeutics","volume":"24","author":"Lipov\u0161ek","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.metabol.2024.156064_bb1270","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","article-title":"Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering","volume":"350","author":"Mitchell","year":"2014","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.metabol.2024.156064_bb1275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb1280","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden","volume":"38","author":"Landlinger","year":"2017","journal-title":"CETP mice European Heart Journal"},{"key":"10.1016\/j.metabol.2024.156064_bb1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1457-8","article-title":"Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1290","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1021\/acsbiomaterials.9b00434","article-title":"PCSK9 hapten multicopy displayed onto carrier protein nanoparticle: an antiatherosclerosis vaccine","volume":"5","author":"You","year":"2019","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.metabol.2024.156064_bb1295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191895","article-title":"Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice","volume":"13","author":"Kawakami","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb1300","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.metabol.2024.156064_bb1305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-13069-w","article-title":"A therapeutic peptide vaccine against PCSK9","volume":"7","author":"Pan","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb1310","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105222","article-title":"Unlike estrogens that increase PCSK9 levels post-menopause HSP27 vaccination lowers cholesterol levels and atherogenesis due to divergent effects on PCSK9 and LDLR","volume":"161","author":"Maarouf","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1315","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1161\/ATVBAHA.121.315933","article-title":"HSP25 vaccination attenuates atherogenesis via upregulation of LDLR expression, lowering of PCSK9 levels and curbing of inflammation","volume":"41","author":"Chen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb1320","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2024.156064_bb1330","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1335","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2174\/092986710791299948","article-title":"Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin\/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R)","volume":"17","author":"Palmer-Smith","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1340","doi-asserted-by":"crossref","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","article-title":"Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein","volume":"286","author":"Du","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1345","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1350","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ejmech.2015.01.022","article-title":"LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153\u2013421): design, synthesis and biochemical evaluation","volume":"92","author":"Alghamdi","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072113","article-title":"PCSK9 prosegment chimera as novel inhibitors of LDLR degradation","volume":"8","author":"Luna Saavedra","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb1360","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.1039\/C6OB01642A","article-title":"Disrupting the PCSK9\/LDLR protein\u2013protein interaction by an imidazole-based minimalist peptidomimetic","volume":"14","author":"Stucchi","year":"2016","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1365","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2014.09.047","article-title":"Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway","volume":"745","author":"Hao","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb1370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep29931","article-title":"Lupin peptides modulate the protein-protein interaction of PCSK9 with the low density lipoprotein receptor in HepG2 cells","volume":"6","author":"Lammi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb1375","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.3390\/molecules26165094","article-title":"Acanthaster planci inhibits PCSK9 and lowers cholesterol levels in rats","volume":"26","author":"Kamaruddin","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.metabol.2024.156064_bb1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114265","article-title":"Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2","volume":"278","author":"Chae","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb1385","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/foods10020408","article-title":"The cholesterol-lowering effect of Capsella Bursa-Pastoris is mediated via SREBP2 and HNF-1\u03b1-regulated PCSK9 inhibition in obese mice and HepG2 cells","volume":"10","author":"Hwang","year":"2021","journal-title":"Foods"},{"key":"10.1016\/j.metabol.2024.156064_bb1390","first-page":"35","article-title":"Modifying pH-sensitive PCSK9\/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C)","author":"Ben-Naim","year":"2022","journal-title":"Protein Engineering, Design and Selection"},{"key":"10.1016\/j.metabol.2024.156064_bb1395","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/nu12051440","article-title":"Naturally occurring PCSK9 inhibitors","volume":"12","author":"Adorni","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2024.156064_bb1400","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu Rev Biophys"},{"key":"10.1016\/j.metabol.2024.156064_bb1405","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156064_bb1410","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jama.2022.13468","article-title":"Treatment of genetic diseases with CRISPR genome editing","volume":"328","author":"Kan","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2024.156064_bb1415","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148555","article-title":"Moving toward genome-editing therapies for cardiovascular diseases","volume":"132","author":"Musunuru","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2024.156064_bb1420","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cvr\/cvac048","article-title":"CRISPR and cardiovascular diseases","volume":"119","author":"Musunuru","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1425","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156064_bb1430","article-title":"Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors","author":"Davis","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.metabol.2024.156064_bb1435","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo\u2014brief report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb1440","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1445","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.metabol.2024.156064_bb1450","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1455","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41592-018-0146-4","article-title":"Base editing a CRISPR way","volume":"15","author":"Marx","year":"2018","journal-title":"Nat Methods"},{"key":"10.1016\/j.metabol.2024.156064_bb1460","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.tibtech.2019.03.008","article-title":"CRISPR\/Cas-mediated base editing: technical considerations and practical applications","volume":"37","author":"Molla","year":"2019","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.metabol.2024.156064_bb1465","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.metabol.2024.156064_bb1470","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.618406","article-title":"Base and prime editing technologies for blood disorders","volume":"3","author":"Antoniou","year":"2021","journal-title":"Frontiers in Genome Editing"},{"key":"10.1016\/j.metabol.2024.156064_bb1475","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb1480","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.metabol.2024.156064_bb1485","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb1490","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s44161-022-00085-x","article-title":"Chasing LDL cholesterol to the bottom\u2014PCSK9 in perspective","volume":"1","author":"Libby","year":"2022","journal-title":"Nature Cardiovascular Research"},{"key":"10.1016\/j.metabol.2024.156064_bb1495","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1500","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","article-title":"Liver as a target for oligonucleotide therapeutics","volume":"59","author":"Sehgal","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.156064_bb1505","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2024.156064_bb1510","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb1515","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.metabol.2017.02.015","article-title":"siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys","volume":"71","author":"Murphy","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156064_bb1520","doi-asserted-by":"crossref","unstructured":"Jensen KK, Tadin-Strapps M, Wang S-p, Hubert J, Kan Y, Ma Y, et al. Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey [S]. J Lipid Res 2016;57:2150\u201362.","DOI":"10.1194\/jlr.M071498"},{"key":"10.1016\/j.metabol.2024.156064_bb1525","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.metabol.2024.156064_bb1530","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1535","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb1540","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1545","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb1550","first-page":"1","article-title":"Therapeutic oligonucleotides. Therapeutic","author":"Goodchild","year":"2011","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.metabol.2024.156064_bb1555","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1039\/C4MD00184B","article-title":"Antisense oligonucleotides: modifications and clinical trials","volume":"5","author":"Sharma","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.metabol.2024.156064_bb1560","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2013.02.359","article-title":"Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9","volume":"62","author":"van Poelgeest","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2024.156064_bb1565","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.metabol.2024.156064_bb1570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.metabol.2024.156064_bb1575","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.16","article-title":"Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice","volume":"1","author":"Yamamoto","year":"2012","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.metabol.2024.156064_bb1580","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe9117","article-title":"An oral antisense oligonucleotide for PCSK9 inhibition","volume":"13","author":"Gennemark","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1585","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1111\/bcp.15425","article-title":"AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval","volume":"88","author":"Reki\u0107","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb1590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/oli.2008.0161","article-title":"Therapeutic potential of splice-switching oligonucleotides","volume":"19","author":"Bauman","year":"2009","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.metabol.2024.156064_bb1595","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yjmcc.2015.03.009","article-title":"RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form","volume":"82","author":"Rocha","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb1600","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1161\/ATVBAHA.121.316290","article-title":"N-acetyl galactosamine targeting: paving the way for clinical application of nucleotide medicines in cardiovascular diseases","volume":"41","author":"Biessen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2024.156064_bb1605","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucl Acid Ther"},{"key":"10.1016\/j.metabol.2024.156064_bb1610","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40265-024-01995-9","article-title":"Long-term efficacy and tolerability of PCSK9 targeted therapy: a review of the literature","volume":"84","author":"Schonck","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2024.156064_bb1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113957","article-title":"Safety of PCSK9 inhibitors","volume":"156","author":"Grze\u015bk","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2024.156064_bb1620","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system","volume":"98","author":"Poirier","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.metabol.2024.156064_bb1625","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.metabol.2024.156064_bb1630","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP Reports: Innovation in Hepatology"},{"key":"10.1016\/j.metabol.2024.156064_bb1635","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.34067\/KID.0007022021","article-title":"Inhibitory antibodies against PCSK9 reduce surface CD36 and mitigate diet-induced renal lipotoxicity","volume":"3","author":"Byun","year":"2022","journal-title":"Kidney360"},{"key":"10.1016\/j.metabol.2024.156064_bb1640","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11883-022-01057-z","article-title":"Expanding biology of PCSK9: roles in atherosclerosis and beyond","volume":"24","author":"Seidah","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb1645","doi-asserted-by":"crossref","DOI":"10.1038\/srep17559","article-title":"Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics","volume":"5","author":"An","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2024.156064_bb1650","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/1061186X.2021.1992630","article-title":"Nanoliposomes as drug delivery systems: safety concerns","volume":"30","author":"Tereshkina","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.metabol.2024.156064_bb1655","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb1660","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb1665","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.metabol.2024.156064_bb1670","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study","volume":"117","author":"Blom","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1675","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.metabol.2024.156064_bb1680","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.156064_bb1685","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2024.156064_bb1690","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2024.156064_bb1695","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.metabol.2024.156064_bb1700","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2024.156064_bb1705","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2024.156064_bb1710","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1715","first-page":"411","article-title":"A potential long-acting LDL-cholesterol\u2013lowering PCSK9 monoclonal antibody: randomized, placebo-controlled phase 1 studies","volume":"1","author":"Cui","year":"2021","journal-title":"JACC: Asia"},{"key":"10.1016\/j.metabol.2024.156064_bb1720","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/nm1140","article-title":"Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis","volume":"10","author":"Wang","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.156064_bb1725","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156064_bb1730","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/mnfr.201400366","article-title":"Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells","volume":"58","author":"Tai","year":"2014","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.metabol.2024.156064_bb1735","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1074\/jbc.M705831200","article-title":"Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin\/kexin type 9","volume":"283","author":"Kourimate","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.metabol.2024.156064_bb1745","doi-asserted-by":"crossref","first-page":"23667","DOI":"10.1074\/jbc.M112.350181","article-title":"Peroxisome proliferator-activated receptor \u03b3 activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression","volume":"287","author":"Duan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2024.156064_bb1750","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vph.2015.07.001","article-title":"Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre-and postmenopausal women: a randomised study","volume":"76","author":"Graversen","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.metabol.2024.156064_bb1755","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1017\/S0007114515003517","article-title":"Synergic hypocholesterolaemic effect of n-3 PUFA and oestrogen by modulation of hepatic cholesterol metabolism in female rats","volume":"114","author":"Oh","year":"2015","journal-title":"Br J Nutr"},{"key":"10.1016\/j.metabol.2024.156064_bb1760","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3945\/ajcn.111.030114","article-title":"Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial","volume":"95","author":"Bjermo","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2024.156064_bb1765","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.fob.2014.08.003","article-title":"Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin\/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture","volume":"4","author":"Mbikay","year":"2014","journal-title":"FEBS Open Bio"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T05:49:17Z","timestamp":1738993757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524002920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":353,"alternative-id":["S0026049524002920"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156064","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 in metabolism and diseases","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156064"}}